默克、中国无锡药明康德在以色列推出生物技术孵化器

this article was translated to Chinese by Baidu

以色列出生的商人Mori Arkin和生命科学为重点的创投基金pontifax也在合资伙伴，将推出2018

上海的制药公司无锡药明康德集团正在与 Mereck Sorono公司的子公司 Merck KgaA, 2018年初在以色列成立一家制药和生物技术初创公司孵化器。

以色列出生的商人Mori Arkin和生命科学为重点的创投基金pontifax公司也将成为合资企业的一部分。

这些计划是上周在特拉维夫的伙伴们宣布的一项活动中宣布的。

命名 “Explore Bio”孵化器将设在Merck Sorono’s现有的复杂的在Yavne，在以色列中部的一个小镇。一位知情人士说，孵化器已经在评估几家以色列公司的投资，估计每家公司将获得几百万美元的初期投资。 除了资金，孵化器将协助药物开发，提供可行性和市场需求评估，并提供早期指导。 孵化器将不依赖政府的支持，但将完全由合作伙伴提供资金。 目前，参与公司的数量没有上限。 Merck, China’s WuXi AppTec to Launch Biotech Incubator in Israel. Israel-born businessman Mori Arkin and life sciences-focused venture capital fund Pontifax are also partners in the venture, set to launch in 2018 Shanghai-based pharmaceutical company WuXi AppTec Group is partnering with Merck Serono, a subsidiary of company Merck KGaA, to launch a pharma and biotech startup incubator in Israel in early 2018. Mori Arkin and life sciences-focused venture capital fund Pontifax Ltd. will also be part of the venture. The plans were declared last week in an event held by the partners in Tel Aviv. Named “Explore Bio”, the incubator will be located at Merck Serono’s existing complex in Yavne, a town in central Israel. One person familiar with the matter said the incubator is already evaluating investments in several Israeli firms and estimated each company will receive an initial investment of several million dollars. In addition to funding, the incubator will assist with drug development, provide feasibility and market demand assessments, and offer early-stage mentoring. The incubator will not rely on government support, but will be funded entirely by the partners. Currently, there is no upper limit to the number of participating companies.